文献速递MDS 与骨髓增殖性肿瘤血栓与止血白血病

胚系Jak2-R1063H突变干扰正常造血发育并增加血栓形成和白血病转化风险

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.
PubMed 文献 · Leukemia · 2025-08-21

该研究通过Jak2-R1063H敲入小鼠模型和200例MPN患者队列,发现该胚系变异导致小鼠死亡率增加、血小板生成刺激和D-二聚体升高,骨髓分析显示髓系偏斜、巨核细胞生成增强和炎症信号激活,造血干细胞加速衰老和功能下降;在200例MPN患者中10例检出该变异,携带者血栓并发症和疾病进展发生率增加且生存期缩短。

要点

  • Jak2-R1063H敲入小鼠死亡率增加,血小板生成刺激和D-二聚体升高提示血栓并发症。
  • 小鼠骨髓显示髓系偏斜、巨核细胞生成增强和炎症信号激活,造血干细胞加速衰老和功能下降。
  • 200例MPN患者中10例检出胚系JAK2-R1063H,携带者血栓并发症和疾病进展增加且生存期缩短。

核心结论

  • JAK2-R1063H胚系变异是MPN发生、血栓并发症和白血病转化的危险因素。

研究设计与样本

  • 研究采用Jak2-R1063H敲入小鼠模型和来自当地血液学中心的200例MPN患者队列。

主要发现

  • Jak2-R1063H小鼠队列死亡率增加,血小板生成刺激和D-二聚体水平升高,提示血栓并发症。
  • 小鼠骨髓分析显示髓系偏斜、巨核细胞生成增强和炎症信号激活。
  • 造血干细胞的转录和功能实验提示其加速衰老和功能下降。
  • Egr1转录网络(包括Thbs1基因)在衰老小鼠中逐渐增加,强化了Jak2/Stat信号引发的改变。
  • 在小鼠急性髓系白血病模型中,Jak2-R1063H与驱动癌基因协同促进白血病发生。

临床怎么用

  • 作者认为这些发现可能对管理携带JAK2-R1063H胚系变异的MPN患者具有重要临床意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The acquired JAK2-V617F mutation plays a causal role in myeloproliferative neoplasms (MPN). Weakly activating JAK2 germline variants have been associated with MPN risk, but the underlying mechanisms remain unclear. We previously identified the JAK2-R1063H germline variant, which contributes to hereditary MPN and increased disease severity in essential thrombocythemia. Here, we studied alterations in hematopoiesis in Jak2-R1063H knock-in mice. The Jak2-R1063H mouse cohort exhibited increased mortality, stimulated thrombopoiesis and elevated D-dimers levels, indicative of thrombotic complications. Bone marrow analysis revealed myeloid bias, enhanced megakaryopoiesis and activation of inflammatory signaling. Transcriptional and functional assays of hematopoietic stem cells suggested their accelerated aging and functional decline. The Egr1 transcriptional network, including the Thbs1 gene, progressively increased in aging mice, reinforcing alterations initiated by Jak2/Stat signaling. In murine acute myelogenous leukemia models, the Jak2-R1063H cooperated with a driver oncogene in promoting leukemogenesis. Germline JAK2-R1063H was found in 10 of 200 MPN patients from local hematology centers, with a higher minor allele frequency compared to healthy controls. Patients harboring JAK2-R1063H variant exhibited an increased incidence of thrombotic complications and disease progression with shortened survival. In conclusion, our findings identify the JAK2-R1063H germline variant as a risk factor for MPN development, thrombotic complications, and leukemic transformation. Our study, which involves a mouse model and a cohort of 200 MPN patients, characterizes the JAK2-R1063H germline mutation as a risk factor for MPN development, thrombotic complications, and leukemic transformation. These findings may have important clinical implications for managing MPN patients carrying the JAK2-R1063H germline variant.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zimolova V, Burocziova M, Berkova L, et al. Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation. Leukemia. 2025. PMID: 40841769. doi:10.1038/s41375-025-02737-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。